Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 130,72k | Derivative Exercise and Sale | 25,69 - 72,67 | 105,21k | - |
| 2026-05-14 | Dr. Matthew B. KleinCEO & Director | -12,57k | 917,15k | Verkauf | 72,46 - 73,08 | 116,19k | -9,76% |
| 2026-05-08 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,54k | 114,82k | Derivative Exercise and Sale | 46,54 - 79,31 | 105,21k | - |
| 2026-04-06 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,27k | 68,01k | Derivative Exercise and Sale | 39,42 - 69,75 | 105,21k | - |
| 2026-04-02 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -829,00 | 56,36k | Verkauf | 67,99 | 28,51k | -2,83% |
| 2026-04-01 | Dr. Neil AlmsteadChief Technical Operations Officer | -52,00k | 3,59M | Automatic Disposition | 68,89 - 70,30 | 15,71k | -76,80% |
| 2026-03-12 | Dr. Matthew B. KleinCEO & Director | -2,66k | 170,58k | Verkauf | 64,08 | 125,11k | -2,08% |
| 2026-03-10 | Ms. Stephanie Smith OkeyIndependent Director | -15,17k | 551,62k | Derivative Exercise and Sale | 33,63 - 70,00 | 5,67k | - |
| 2026-03-05 | Dr. Neil AlmsteadChief Technical Operations Officer | -3,99k | 252,82k | Automatic Disposition | 63,38 | 67,71k | -5,56% |
| 2026-03-05 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -10,00k | 633,80k | Automatic Disposition | 63,38 | 28,03k | -26,29% |
| 2026-03-05 | Ms. Stephanie Smith OkeyIndependent Director | -6,33k | 401,39k | Automatic Disposition | 63,38 | 5,67k | -52,78% |
| 2026-02-19 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,02k | 209,76k | Automatic Disposition | 68,54 - 69,82 | 105,21k | -2,79% |
| 2026-02-18 | Dr. Neil AlmsteadChief Technical Operations Officer | -3,12k | 216,47k | Verkauf | 69,36 | 71,70k | -4,17% |
| 2026-02-18 | Mr. Eric PauwelsChief Business Officer | -3,02k | 209,40k | Verkauf | 69,36 | 25,12k | -10,73% |
| 2026-02-18 | Mr. Pierre GravierCFO | -2,99k | 207,53k | Verkauf | 69,36 | 27,94k | -9,67% |
| 2026-02-18 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -2,48k | 172,29k | Verkauf | 69,36 | 52,38k | -4,53% |
| 2026-02-18 | Ms. Christine UtterSenior VP, CAO & Head of People Services | -2,49k | 172,98k | Verkauf | 69,36 | 39,45k | -5,95% |
| 2026-02-18 | Dr. Matthew B. KleinCEO & Director | -7,37k | 511,25k | Verkauf | 69,36 | 121,77k | -5,71% |
| 2026-02-17 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 122,65k | Derivative Exercise and Sale | 25,69 - 70,13 | 64,48k | - |
| 2026-02-18 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,08k | 213,70k | Verkauf | 69,36 | 64,48k | -4,56% |
| 2026-01-08 | Dr. Neil AlmsteadChief Technical Operations Officer | -940,00 | 71,86k | Verkauf | 76,45 | 72,41k | -1,28% |
| 2026-01-08 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -1,29k | 98,31k | Verkauf | 76,45 | 66,61k | -1,89% |
| 2026-01-08 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -5,06k | 390,77k | Automatic Disposition | 76,56 - 79,52 | 66,61k | -7,06% |
| 2026-01-08 | Mr. Eric PauwelsChief Business Officer | -1,45k | 111,16k | Verkauf | 76,45 | 27,29k | -5,06% |
| 2026-01-08 | Mr. Eric PauwelsChief Business Officer | -5,89k | 454,79k | Automatic Disposition | 76,42 - 78,70 | 27,29k | -17,76% |
| 2026-01-08 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -866,00 | 66,21k | Verkauf | 76,45 | 39,65k | -2,14% |
| 2026-01-08 | Dr. Matthew B. KleinCEO & Director | -2,51k | 192,20k | Verkauf | 76,45 | 106,39k | -2,31% |
| 2026-01-08 | Ms. Christine UtterSenior VP, CAO & Head of People Services | -1,03k | 79,05k | Verkauf | 76,45 | 37,59k | -2,68% |
| 2026-01-06 | Ms. Christine UtterSenior VP, CAO & Head of People Services | -2,62k | 201,92k | Verkauf | 76,95 - 77,45 | 38,63k | -6,34% |
| 2026-01-06 | Dr. Neil AlmsteadChief Technical Operations Officer | -2,41k | 186,10k | Verkauf | 76,95 - 77,48 | 73,35k | -3,18% |
| 2026-01-06 | Mr. Eric PauwelsChief Business Officer | -3,14k | 242,42k | Verkauf | 76,95 - 77,48 | 34,64k | -8,31% |
| 2026-01-06 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -1,98k | 152,86k | Verkauf | 76,95 - 77,48 | 40,51k | -4,66% |
| 2026-01-06 | Dr. Matthew B. KleinCEO & Director | -8,17k | 629,90k | Verkauf | 76,95 - 77,48 | 108,90k | -6,97% |
| 2026-01-06 | Mr. Pierre GravierCFO | -2,14k | 164,60k | Verkauf | 76,95 | 24,64k | -7,99% |
| 2026-01-07 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,38k | 132,75k | Derivative Exercise and Sale | 38,10 - 78,98 | 72,96k | - |
| 2026-01-06 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,24k | 250,27k | Verkauf | 76,95 - 77,48 | 72,96k | -4,25% |
| 2026-01-05 | Ms. Emma ReeveIndependent Director | -734,00 | 21,62k | Derivative Exercise and Sale | 46,54 - 76,00 | 6,67k | - |
| 2026-01-02 | Dr. Glenn Daniel SteeleIndependent Director | -12,00k | 545,88k | Derivative Exercise and Sale | 30,86 - 76,35 | 16,17k | - |
| 2026-01-05 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,27k | 81,87k | Derivative Exercise and Sale | 39,42 - 76,79 | 67,45k | - |
| 2025-12-30 | Dr. Matthew B. KleinCEO & Director | -8,09k | 619,94k | Verkauf | 76,64 | 92,81k | -8,02% |
| 2025-12-19 | Mr. Eric PauwelsChief Business Officer | -20,51k | 248,16k | Derivative Exercise and Sale | 18,01 - 78,43 | 17,52k | - |
| 2025-12-17 | Mr. Eric PauwelsChief Business Officer | -43,49k | 578,26k | Derivative Exercise and Sale | 18,01 - 76,00 | 17,52k | - |
| 2025-12-16 | Mr. Michael SchmertzlerIndependent Chairman of the Board | 24,00k | 740,64k | Derivative Exercise and Retained Stock | 30,86 | 1,54M | 1,59% |
| 2025-12-03 | Ms. Emma ReeveIndependent Director | -733,00 | 23,51k | Derivative Exercise and Sale | 46,54 - 78,62 | 4,33k | - |
| 2025-12-02 | Dr. Matthew B. KleinCEO & Director | -3,43k | 271,05k | Verkauf | 79,07 | 82,15k | -4,01% |
| 2025-11-24 | Dr. Neil AlmsteadChief Technical Operations Officer | -107,50k | 5,57M | Derivative Exercise and Sale | 18,01 - 85,37 | 56,54k | - |
| 2025-11-24 | Dr. Allan Steven JacobsonCo-Founder & Independent Director | -26,00k | 1,75M | Derivative Exercise and Sale | 11,23 - 85,32 | 15,12k | - |
| 2025-11-21 | Ms. Emma ReeveIndependent Director | -10,00k | 283,40k | Derivative Exercise and Sale | 51,16 - 79,50 | 4,33k | - |
| 2025-11-20 | Ms. Stephanie Smith OkeyIndependent Director | -867,00 | 0,00 | Other Disposition | - | 5,67k | -13,27% |
| 2025-11-17 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 141,45k | Derivative Exercise and Sale | 25,69 - 77,18 | 103,90k | - |
| 2025-11-12 | Ms. Emma ReeveIndependent Director | -7,33k | 205,03k | Derivative Exercise and Sale | 46,54 - 74,50 | 4,33k | - |
| 2025-10-30 | Ms. Emma ReeveIndependent Director | -12,00k | 376,80k | Derivative Exercise and Sale | 38,10 - 69,50 | 4,33k | - |
| 2025-10-30 | Ms. Emma ReeveIndependent Director | -3,67k | 254,79k | Automatic Disposition | 69,50 | 4,33k | -45,83% |
| 2025-10-07 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,38k | 85,50k | Derivative Exercise and Sale | 38,10 - 64,97 | 103,90k | - |
| 2025-10-03 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -24,92k | 656,16k | Derivative Exercise and Sale | 39,42 - 67,15 | 103,90k | - |
| 2025-10-03 | Dr. Neil AlmsteadChief Technical Operations Officer | -55,00k | 1,94M | Derivative Exercise and Sale | 30,86 - 67,16 | 56,54k | - |
| 2025-10-03 | Dr. Allan Steven JacobsonCo-Founder & Independent Director | -12,00k | 409,68k | Derivative Exercise and Sale | 30,86 - 65,00 | 15,12k | - |
| 2025-10-03 | Ms. Emma ReeveIndependent Director | -25,56k | 772,69k | Derivative Exercise and Sale | 33,02 - 66,93 | 8,00k | - |
| 2025-09-11 | Ms. Emma ReeveIndependent Director | -10,84k | 359,75k | Derivative Exercise and Sale | 25,69 - 59,50 | 8,00k | - |
| 2025-09-11 | Ms. Emma ReeveIndependent Director | -4,87k | 289,65k | Automatic Disposition | 59,50 | 8,00k | -37,83% |
| 2025-09-11 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -47,25k | 1,09M | Derivative Exercise and Sale | 38,10 - 62,09 | 103,90k | - |
| 2025-09-09 | Mr. David P. SouthwellIndependent Director | -12,00k | 329,76k | Derivative Exercise and Sale | 30,86 - 58,34 | 14,52k | - |
| 2025-09-08 | Mr. Eric PauwelsChief Business Officer | -39,85k | 1,36M | Derivative Exercise and Sale | 11,23 - 56,94 | 20,06k | - |
| 2025-08-28 | Dr. Allan Steven JacobsonCo-Founder & Independent Director | -1,67k | 83,60k | Verkauf | 50,15 | 15,12k | -9,93% |
| 2025-08-15 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 64,39k | Derivative Exercise and Sale | 25,69 - 48,58 | 103,90k | - |
| 2025-08-05 | Dr. Matthew B. KleinCEO & Director | -10,74k | 555,64k | Verkauf | 51,74 | 77,77k | -12,13% |
| 2025-07-15 | Mr. Pierre GravierCFO | -2,52k | 124,44k | Verkauf | 49,46 | 20,62k | -10,87% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
